SE8800731L - Fenylkarbamat - Google Patents

Fenylkarbamat

Info

Publication number
SE8800731L
SE8800731L SE8800731A SE8800731A SE8800731L SE 8800731 L SE8800731 L SE 8800731L SE 8800731 A SE8800731 A SE 8800731A SE 8800731 A SE8800731 A SE 8800731A SE 8800731 L SE8800731 L SE 8800731L
Authority
SE
Sweden
Prior art keywords
ethyl
phenylcarbamate
phenylncarbamate
dimethylamino
pharmaceutical
Prior art date
Application number
SE8800731A
Other languages
English (en)
Swedish (sv)
Other versions
SE8800731D0 (sv
SE8800731A0 (sv
Inventor
A Enz
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6322236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE8800731(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of SE8800731D0 publication Critical patent/SE8800731D0/xx
Publication of SE8800731L publication Critical patent/SE8800731L/xx
Publication of SE8800731A0 publication Critical patent/SE8800731A0/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SE8800731A 1987-03-04 1988-03-02 Fenylkarbamat SE8800731A0 (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3706914 1987-03-04

Publications (3)

Publication Number Publication Date
SE8800731D0 SE8800731D0 (sv) 1988-03-02
SE8800731L true SE8800731L (sv) 1988-09-05
SE8800731A0 SE8800731A0 (sv) 1988-09-05

Family

ID=6322236

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8800731A SE8800731A0 (sv) 1987-03-04 1988-03-02 Fenylkarbamat

Country Status (29)

Country Link
US (1) US5602176A (cs)
JP (3) JP2625478B2 (cs)
KR (1) KR0133686B1 (cs)
AT (1) AT394190B (cs)
AU (1) AU618949B2 (cs)
BE (1) BE1001467A3 (cs)
CA (1) CA1307003C (cs)
CH (1) CH675720A5 (cs)
CS (1) CS411091A3 (cs)
CY (1) CY1735A (cs)
DK (1) DK175762B1 (cs)
ES (1) ES2010527A6 (cs)
FI (1) FI89165C (cs)
FR (1) FR2611707B1 (cs)
GB (1) GB2203040C (cs)
GR (1) GR1000023B (cs)
HK (1) HK110093A (cs)
HU (1) HU201906B (cs)
IE (1) IE61714B1 (cs)
IL (1) IL85609A (cs)
IT (1) IT1219853B (cs)
LU (2) LU87150A1 (cs)
MY (1) MY103225A (cs)
NL (1) NL195004C (cs)
NZ (1) NZ223714A (cs)
PT (1) PT86875B (cs)
SA (1) SA93140384B1 (cs)
SE (1) SE8800731A0 (cs)
ZA (1) ZA881584B (cs)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
FI964113A7 (fi) * 1994-04-15 1996-10-14 Iyo Masaomi Lääkekoostumus hoitamaan tardiivia dyskinesiaa ja sen käyttö
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
DK0951284T3 (da) * 1996-12-18 2004-02-16 Teva Pharma Phenylethylminderivater
ATE292619T1 (de) 1996-12-18 2005-04-15 Teva Pharma Aminoindanderivate
GB9800526D0 (en) * 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
US6316023B1 (en) * 1998-01-12 2001-11-13 Novartis Ag TTS containing an antioxidant
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
KR100603900B1 (ko) 1998-10-01 2006-07-25 노파르티스 아게 신규의 서방성 경구 제제
US20040209849A1 (en) * 1998-11-27 2004-10-21 Sanochemia Pharmazeutika Aktiengesellschaft Use of effectors of the central cholinergic nervous system for treatment of delirium
AU2354400A (en) * 1998-12-11 2000-06-26 Bonnie Davis Use of acetylcholinesterase inhibitors on the modulation of the hypothalamic-pituitary-gonadal axis
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
US6534541B1 (en) 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders
CA2406383A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research A.beta.42 lowering agents
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
CZ293014B6 (cs) 2002-10-24 2004-01-14 Léčiva, A.S. Způsob výroby (-)-(S)-3-[1-(dimethylamino)ethyl]fenyl-N-ethyl-N-methylkarbamátu
CA2502432A1 (en) * 2002-10-24 2004-05-06 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
JP2007528857A (ja) * 2003-07-11 2007-10-18 ミリアド ジェネティクス， インコーポレイテッド アルツハイマー病の処置のための薬学的方法、投与レジメンおよび投薬形態
EP2314571A3 (en) * 2003-10-21 2011-08-31 CoLucid Pharmaceuticals, Inc. Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
GB2409453A (en) * 2003-12-24 2005-06-29 Generics Process for the preparation of aminoalkyl phenylcarbamates
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
WO2005108683A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
JPWO2006004201A1 (ja) * 2004-07-01 2008-04-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 神経再生促進剤
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
CA2618985A1 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
KR101168211B1 (ko) * 2004-11-08 2012-07-25 엠큐어 파마슈티컬즈 리미티드 （ｓ）－３－［（１－디메틸아미노）에틸］－페닐－ｎ－에틸－ｎ－메틸－카바메이트의 제조를 위한 효과적인 방법
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
JP2009502807A (ja) * 2005-07-22 2009-01-29 ミリアド ジェネティクス， インコーポレイテッド 薬剤含有率の高い製剤および投与量形態
ES2267399B1 (es) 2005-08-04 2008-02-01 Ragactives, S.L. Procedimiento para la obtencion de carbamatos de fenilo.
ATE546202T1 (de) 2005-09-15 2012-03-15 Sony Computer Entertainment Inc Kabelloser videospielcontroller und verfahren zum betreiben des kabellosen videospielcontrollers
TWI389709B (zh) 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
EP1956904B1 (en) * 2005-12-09 2017-04-12 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Low-dose ladostigil for the treatment of mild cognitive impairment
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US7767843B2 (en) * 2006-03-02 2010-08-03 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
DE602006015241D1 (de) * 2006-08-17 2010-08-12 Alembic Ltd Verbessertes verfahren zur herstellung von rivastigmin
WO2008037433A1 (en) 2006-09-29 2008-04-03 Synthon B.V. Process for making aminoalkylphenyl carbamates and intermediates therefor
WO2008051599A2 (en) 2006-10-27 2008-05-02 Medivation Neurology, Inc. Combination therapies for treating alzheimer's disease using i. a. dimebon and dolepezil
EP1942100A1 (en) * 2007-01-04 2008-07-09 Krka Tovarna Zdravil, D.D., Novo Mesto Amorphous and crystalline forms of rivastigmine hydrogentartrate
EP2125709A2 (en) * 2007-02-02 2009-12-02 Colucid Pharmaceuticals, Inc. Compounds that inhibit cholinesterase
US8013181B2 (en) * 2007-04-10 2011-09-06 Dr. Reddy's Laboratories Limited Preparation of rivastigmine and its salts
CN101707952B (zh) * 2007-04-16 2012-08-29 上海特化医药科技有限公司 一种制备利伐斯的明的方法及其中间体
US7884121B2 (en) * 2007-06-11 2011-02-08 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
WO2009011901A2 (en) * 2007-07-18 2009-01-22 Colucid Pharmaceuticals, Inc. Methods for promoting wakefulness
US8593728B2 (en) * 2009-02-19 2013-11-26 Toyota Motor Engineering & Manufacturing North America, Inc. Multilayer photonic structures
US20090082436A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched rivastigmine
EP2233465B1 (en) * 2008-01-10 2017-06-28 Shanghai Institute of Pharmaceutical Industry Preparation method of rivastigmine, its intermediates and preparation method of the intermediates
WO2010023535A1 (en) 2008-08-25 2010-03-04 Jubilant Organosys Limited A process for producing (s)-3-[(1-dimethylamino)ethyl] phenyl-n-ethyl-n-methyl-carbamate via novel intermediates
US20100087768A1 (en) * 2008-10-02 2010-04-08 Forlano Paula Transdermal drug delivery system for liquid active ingredient
GB0823554D0 (en) * 2008-12-24 2009-01-28 Novartis Ag Process for the preparation of optically active compounds using transfer hydrogenation
CN101823970B (zh) * 2009-03-03 2013-05-08 江苏恩华药业股份有限公司 卡巴拉汀及其中间体的合成方法
PT2515886T (pt) 2009-12-22 2018-05-23 Luye Pharma Ag Sistema terapêutico transdermal para a administração de rivastigmina ou de seus derivados
US10076502B2 (en) 2009-12-22 2018-09-18 Luye Pharma Ag Transdermal therapeutic system for administering rivastigmine or derivatives thereof
ES2363395B1 (es) * 2010-01-20 2012-02-23 Farmalider, S.A. Composición farmacéutica l�?quida de rivastigmina o de una de sus sales de adición de �?cido para la administración por v�?a oral.
CN102905532A (zh) * 2010-02-09 2013-01-30 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
EP2552489A1 (en) 2010-03-29 2013-02-06 Novartis AG Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant
WO2011151669A1 (en) 2010-06-02 2011-12-08 Jubilant Life Sciences Limited Process for producing enantiomerically enriched isomer of 3-(1-aminoethyl) phenyl derivative and employing the same to produce rivastigmine or its pharmaceutically acceptable salt
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
EP2582799B1 (en) 2010-06-17 2017-12-20 Codexis, Inc. Biocatalysts and methods for the synthesis of (s)-3-(1-aminoethyl)-phenol
DK3034079T3 (en) 2010-11-15 2018-02-05 Agenebio Inc PYRIDAZINE DERIVATIVES, COMPOSITIONS AND PROCEDURES FOR TREATING COGNITIVE WEAKNESS
EP2468274B1 (de) 2010-12-14 2015-07-01 Acino AG Transdermales therapeutisches System zur Verabreichung eines Wirkstoffs
CN102786441B (zh) 2011-05-18 2013-11-13 浙江海正药业股份有限公司 利凡斯的明的制备方法、其中间体以及中间体的制备方法
WO2012161489A2 (ko) 2011-05-20 2012-11-29 에스케이케미칼 주식회사 리바스티그민 함유 패취
AR082640A1 (es) * 2011-08-25 2012-12-19 Amarin Technologies S A Un dispositivo para la administracion transdermal de compuestos alcalinos susceptibles a la degradacion en su forma no salificada
CN103796645B (zh) 2011-08-31 2017-06-20 东洋油墨Sc控股株式会社 贴剂
CN103073456B (zh) * 2011-10-26 2014-03-19 连云港润众制药有限公司 重酒石酸卡巴拉汀中间体的制备方法
EP2594261A1 (en) 2011-11-18 2013-05-22 Labtec GmbH Composition for transdermal administration of rivastigmine
WO2013142339A1 (en) 2012-03-23 2013-09-26 Novartis Ag Transdermal therapeutic system and method
ES2449215B1 (es) * 2012-09-17 2014-07-14 Galenicum Health S.L. Solución oral de (S)-3-[1-(dimetilamino)etil]fenil N-etil-N-metilcarbamato
KR20140038237A (ko) 2012-09-20 2014-03-28 에스케이케미칼주식회사 리바스티그민의 안정성이 개선된 의약품
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN103896787A (zh) * 2012-12-26 2014-07-02 江苏康倍得药业有限公司 一种卡巴拉汀前体[1-(3-甲氧基苯基)乙基]二甲胺的制备方法
WO2014111790A2 (en) 2013-01-15 2014-07-24 Zydus Technologies Limited Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
HK1218623A1 (zh) 2013-03-15 2017-03-03 艾吉因生物股份有限公司 用於改善認知功能的方法和組合物
CN103319374B (zh) * 2013-06-09 2015-04-22 无锡佰翱得生物科学有限公司 一种(s)-卡巴拉汀的不对称合成方法
CA2921308A1 (en) 2013-08-16 2015-02-19 Universiteit Maastricht Treatment of cognitive impairment with pde4 inhibitor
JP6883988B2 (ja) 2013-12-20 2021-06-09 エージンバイオ， インコーポレイテッド ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
JP6899043B2 (ja) 2015-05-22 2021-07-07 エージンバイオ， インコーポレイテッド レベチラセタムの持続放出性医薬組成物
AU2016279052A1 (en) 2015-06-19 2018-02-15 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JP7514534B2 (ja) 2018-06-19 2024-07-11 エージンバイオ， インコーポレイテッド 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
KR20200035359A (ko) 2018-09-26 2020-04-03 캐딜라 파마슈티클즈 리미티드 리바스티그민 제조용 중간체의 합성
IL319072A (en) 2022-08-19 2025-04-01 Agenebio Inc History of Benzazepine, Compositions and Methods for Treating Cognitive Impairment
WO2025038382A1 (en) 2023-08-11 2025-02-20 Momentive Performance Materials Inc. Pharmaceutical adhesive compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469700A (en) * 1981-06-19 1984-09-04 Lowell M. Somers Benzoylecgonine or benzoylnorecgonine as active agents for the treatment of rheumatoid arthritis
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.

Also Published As

Publication number Publication date
KR0133686B1 (ko) 1998-04-21
GB8804888D0 (en) 1988-03-30
DK112588D0 (da) 1988-03-02
NL195004C (nl) 2003-11-04
IL85609A0 (en) 1988-08-31
FI880972L (fi) 1988-09-05
FR2611707A1 (fr) 1988-09-09
AU1255488A (en) 1988-09-08
IT1219853B (it) 1990-05-24
JPS63238054A (ja) 1988-10-04
FR2611707B1 (fr) 1990-04-20
SA93140384B1 (ar) 2006-04-04
US5602176A (en) 1997-02-11
SE8800731D0 (sv) 1988-03-02
ZA881584B (en) 1989-11-29
GB2203040C (en) 2014-07-30
GR1000023B (el) 1990-01-31
NL195004B (nl) 2003-07-01
MY103225A (en) 1993-05-29
JP2625478B2 (ja) 1997-07-02
CY1735A (en) 1994-06-03
AU618949B2 (en) 1992-01-16
IL85609A (en) 1992-07-15
IE61714B1 (en) 1994-11-30
AT394190B (de) 1992-02-10
JP2859225B2 (ja) 1999-02-17
HK110093A (en) 1993-10-29
JPH09165362A (ja) 1997-06-24
IT8847693A0 (it) 1988-03-04
BE1001467A3 (fr) 1989-11-07
KR880011088A (ko) 1988-10-26
LU87150A1 (fr) 1988-11-17
DK175762B1 (da) 2005-02-14
GR880100125A (en) 1989-01-31
IE880583L (en) 1988-09-04
HUT49325A (en) 1989-09-28
FI89165B (fi) 1993-05-14
NZ223714A (en) 1994-05-26
DK112588A (da) 1988-09-05
PT86875B (pt) 1992-05-29
JPH09118617A (ja) 1997-05-06
CH675720A5 (cs) 1990-10-31
FI89165C (fi) 1993-08-25
CA1307003C (en) 1992-09-01
CS411091A3 (en) 1992-12-16
PT86875A (pt) 1988-04-01
LU90297I2 (fr) 1998-12-07
ES2010527A6 (es) 1989-11-16
NL8800436A (nl) 1988-10-03
ATA55188A (de) 1991-08-15
HU201906B (en) 1991-01-28
GB2203040B (en) 1990-10-24
FI880972A0 (fi) 1988-03-02
SE8800731A0 (sv) 1988-09-05
GB2203040A (en) 1988-10-12

Similar Documents

Publication Publication Date Title
SE8800731L (sv) Fenylkarbamat
SE7602317L (sv) 1,4-dihydropyridinkarbonsyraalkylestrar till anvendning som lekemedel och sett att framstella desamma
BG47033A3 (en) Method for preparing of derivatives of imidazolamine
NL300084I2 (nl) Nieuwe thiofeencarbonzuur-esters van aminoalkoholen, hun kwaternairiseringsprodukten, alsmede de bereiding en toepassing van deze verbindingen.
MY105121A (en) Pharmaceutical composition for systemic transdermal administration.
PT88404A (pt) Dosage form comprising fast agent delivery followed by slow agent delivery
ATE106860T1 (de) R-enantiomer von n-propargyl-1-aminoindan, dessen herstellung und dieses enthaltende pharmazeutische zusammensetzungen.
DE3889220D1 (de) Zeigerbenutzende anzeige.
DE3787377D1 (de) Eindringungserhöhende mittel zur transdermalen verabreichung systemischer mittel.
IT8621358A0 (it) Composizione farmaceutica adattivita' analgesica.
IS1565B (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
IT8721411A0 (it) Composizione farmaceutica idrosolubile contenente n acetilsisteina.
ES468525A1 (es) Procedimiento para la obtencion de nuevas 2-alquilenaminodi-hidropiridinas
DK0460062T3 (da) Huperzin A-analoger
IT1057132B (it) Bendaggio stratificato per la somministrazione di scopolamina per via transdermica
IT8721410A0 (it) Composizione farmaceutica idrosolubile contenente n acetilcisteina.
FI884598A7 (fi) Aminosyraderivat.
ES2013796A6 (es) Agente cosmetico a base de derivados de pirimidina y retinoides, y procedimiento para prepararlo.
DE3787657D1 (de) Aminosäure-Derivate.
DK131887A (da) 1,2,3,4-tetrahydro-3-carbamoyl-2-thioxo/oxo-5-pyrimidencarboxylsyre-derivater og deres anvendelse som laegemidler
IT8722501A0 (it) Formulazioni farmaceutiche per somministrazione transdermica.
FR2321294A1 (fr) Derives d'acides 7b-amino-3-cephem-3-carbonylmethyl-4-carboxyliques utiles comme medicaments
ES2118248T3 (es) Esteres y amidas de 9-cloro-prostaglandina y su empleo para preparar medicamentos.
ES8502435A1 (es) Un metodo para preparar 2(1h)-piridinonas
NO881152D0 (no) Farmasoeytisk blanding.

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 8800731-5